BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare

Rhea-AI Summary

BillionToOne (NASDAQ: BLLN) announced a collaboration with Epic to integrate its prenatal and oncology tests into Epic's Aura diagnostics suite. The agreement, signed in December 2025, enables clinicians to order UNITY Complete prenatal testing and Northstar Select and Northstar Response liquid biopsy tests directly in Epic, with discrete results flowing back into the EHR and MyChart. The integration aims to simplify ordering, speed clinical decision making, and improve the patient and provider experience across health systems, maternal-fetal medicine, and oncology settings.

Positive

• Signed integration with Epic in December 2025
• Orders for UNITY Complete, Northstar Select, and Northstar Response available inside Epic
• Results flow into Epic EHR and MyChart to support faster decisions
• UNITY Complete provides fetal risk assessment for up to 14 conditions from one maternal blood sample

Negative

• None.

News Market Reaction

+0.37% 2.1x vol

9 alerts

+0.37% News Effect

-2.4% Trough in 57 min

+$15M Valuation Impact

$4.03B Market Cap

2.1x Rel. Volume

On the day this news was published, BLLN gained 0.37%, reflecting a mild positive market reaction. Argus tracked a trough of -2.4% from its starting point during tracking. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $15M to the company's valuation, bringing the market cap to $4.03B at that time. Trading volume was elevated at 2.1x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Genetic conditions covered: up to 14 conditions

1 metrics

Genetic conditions covered up to 14 conditions UNITY Complete prenatal test coverage

Market Reality Check

Price: $86.05 Vol: Volume 341,711 vs 20-day ...

normal vol

$86.05 Last Close

Volume Volume 341,711 vs 20-day average 235,439 (relative volume 1.45). normal

Technical Price 94.37 is trading below 200-day MA at 99.7, and 31.96% below 52-week high 138.7.

Peers on Argus

No peers in momentum scanner and no same-day peer headlines; current -2.56% move...

No peers in momentum scanner and no same-day peer headlines; current -2.56% move appears stock-specific rather than sector-driven.

Historical Context

5 past events · Latest: Jan 12 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 12	Guidance update	Positive	+15.4%	Issued 2026 guidance with strong implied revenue growth and profitability.
Jan 06	Clinical study win	Positive	-0.1%	Northstar Select chosen as new plasma genomic test for LC-SCRUM-TRY.
Dec 23	Conference participation	Positive	-9.6%	Announced participation in 44th Annual J.P. Morgan Healthcare Conference.
Dec 09	Board appointment	Positive	+4.7%	Appointed Anthony Pagano as Director and Audit Committee Chair.
Dec 09	Earnings results	Positive	+4.7%	Reported strong Q3 2025 growth, margins, and positive operating income.

Pattern Detected

Positive fundamentals and strategic updates have often seen supportive price reactions, but some non-fundamental news (e.g., conference participation) showed negative divergence.

Recent Company History

Over the past six weeks, BillionToOne reported strong Q3 2025 results with $83.5M revenue and positive profitability metrics, followed by guidance implying ~40%–45% revenue growth in 2026. The company also strengthened governance with a new Audit Committee Chair and highlighted participation in the J.P. Morgan Healthcare Conference. Clinical traction continued with Northstar Select’s role in the LC-SCRUM-TRY study. Today’s Epic collaboration extends that trajectory by embedding UNITY and Northstar testing directly into EHR workflows.

Market Pulse Summary

This announcement expands BillionToOne’s reach by integrating UNITY Complete and Northstar liquid bi...

Analysis

This announcement expands BillionToOne’s reach by integrating UNITY Complete and Northstar liquid biopsy tests directly into Epic’s electronic health record workflows. It follows strong Q3 2025 financial performance and guidance pointing to substantial growth in 2026. Investors may focus on how quickly ordering through Epic translates into higher test volumes, broader access across prenatal and oncology settings, and sustained profitability as the molecular diagnostics platform scales.

Key Terms

electronic health record, ehr, liquid biopsy, aneuploidies, +1 more

5 terms

electronic health record technical

"Epic, the nation's most widely used comprehensive electronic health record (EHR)."

A digital version of a patient’s medical chart that collects health information — diagnoses, medications, lab results, imaging and doctors’ notes — in one place so authorized clinicians can view and update it. For investors, electronic health records matter because they drive revenue and costs for companies that build, sell or rely on them, influence how quickly care is delivered, and create opportunities (and risks) tied to data access, software updates, regulation and patient privacy. Think of it as an online file cabinet for health that affects how the healthcare system runs and spends money.

ehr technical

"By integrating our tests directly into the EHR, we're helping clinicians..."

EHR stands for electronic health record, a digital version of a patient’s complete medical file that replaces paper charts and collects diagnoses, medications, test results and treatment history in one place. For investors, EHR systems matter because they drive recurring revenue for software and services, affect healthcare providers’ costs and efficiency, and create data assets and integration opportunities that can influence a company’s growth and regulatory risk.

liquid biopsy medical

"Northstar Select® and Northstar Response® liquid biopsy tests directly within Epic."

A liquid biopsy is a laboratory test that looks for tiny pieces of tumor or disease-related material — such as DNA, proteins, or cells — circulating in blood or other body fluids, allowing detection and monitoring without a surgical tissue sample. For investors, it matters because these tests can speed diagnosis, guide treatment choices, enable easier repeat testing, and create recurring revenue streams if adopted widely, affecting a medical company's growth and regulatory risk profile.

aneuploidies medical

"risk assessment for up to 14 recessive and X-linked conditions, aneuploidies, and more..."

Aneuploidies are conditions where cells have an abnormal number of chromosomes—like a recipe with missing or extra pages that changes the final dish. They matter to investors because aneuploidies drive demand for diagnostic tests, influence the development and approval of therapies, and affect the commercial prospects and regulatory risk of companies working in prenatal screening, oncology, and genetic medicine.

molecular diagnostics medical

"a next-generation molecular diagnostics company with a mission to create powerful..."

Molecular diagnostics are laboratory tests that look for specific molecules — such as genes, pieces of DNA or RNA, or proteins — to detect disease, predict risk, or guide treatment choices. For investors, these tests matter because they can change how illnesses are diagnosed and treated, create recurring revenue through specialized tests and companion products, and face clear regulatory and reimbursement pathways that drive commercial value; think of them as reading a biological barcode to inform medical decisions.

AI-generated analysis. Not financial advice.

Integration enables seamless ordering and results delivery within Epic for UNITY Complete® and Northstar® tests, creating a better patient and provider experience

MENLO PARK, Calif., Jan. 15, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic, the nation's most widely used comprehensive electronic health record (EHR). The agreement, signed in December 2025, will integrate BillionToOne's prenatal and oncology testing portfolio with Epic's Aura diagnostics suite.

Through the integration, clinicians will be able to order BillionToOne's UNITY Complete® prenatal test as well as Northstar Select® and Northstar Response® liquid biopsy tests directly within Epic. Discrete test results then flow back into the electronic health record, where they can power downstream clinical decision support and a simpler experience for patients and providers in health systems, community practices, maternal-fetal medicine practices, and oncology clinics.

"Collaborating with Epic advances our goal of making high-quality molecular diagnostics easier to access and simpler to use in everyday clinical care," said Oguzhan Atay, co-founder and CEO of BillionToOne. "By integrating our tests directly into the EHR, we're helping clinicians spend less time navigating logistics and more time focusing on patient care, whether supporting expectant families or guiding cancer treatment decisions."

UNITY Complete is the first and only clinically validated non-invasive prenatal test to provide direct fetal risk assessment for up to 14 recessive and X-linked conditions, aneuploidies, and more from a single maternal blood sample. For oncology care, Northstar Select helps identify appropriate therapies for patients with advanced cancer, while Northstar Response enables treatment monitoring over time.

With results delivered directly into Epic and available through the MyChart patient portal, the integration supports faster clinical decision making and a more connected patient experience.

"BillionToOne's use of Aura integrates oncology and prenatal tests and results where they matter—inside the clinician's workflow, at the moment of decision," said Seth Hain, senior vice president of research and development at Epic.

About BillionToOne
Headquartered in Menlo Park, California, BillionToOne is a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all. The company's patented Quantitative Counting Templates™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level. For more information, visit www.billiontoone.com.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of federal securities laws. These forward-looking statements generally are identified by the words "believe," "project," "expect," "anticipate," "estimate," "intend," "strategy," "future," "opportunity," "plan," "may," "should," "will," "would," "will be," "will continue," "will likely result," and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Forward-looking statements in this press release include, but are not limited to, statements regarding the adoption of BillionToOne's tests due to the integration with Epic.   These statements are based on management's current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, some of which are beyond BillionToOne's control. These and additional risks and uncertainties could affect BillionToOne's financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. These risks and uncertainties include, but are not limited to, the risk that integration with Epic will not be successful and increased adoption of BillionToOne's tests will not increase and those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operation" and elsewhere in BillionToOne's most recently filed Quarterly Report on Form 10-Q, and other filing we make with the Securities and Exchange Commission from time to time. The forward-looking statements in this press release are based on information available to BillionToOne as of the date hereof, and BillionToOne disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing BillionToOne's views as of any date subsequent to the date of this press release.

Media Contact
billiontoone@moxiegrouppr.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/billiontoone-announces-collaboration-with-epic-to-expand-prenatal-and-oncology-testing-across-healthcare-302662474.html

SOURCE BillionToOne

FAQ

What did BillionToOne (BLLN) announce about Epic on January 15, 2026?

BillionToOne announced a collaboration to integrate its prenatal and oncology tests with Epic's Aura, enabling ordering and results delivery inside Epic.

Which BillionToOne tests will be available in Epic for BLLN patients and clinicians?

UNITY Complete prenatal test and Northstar Select and Northstar Response liquid biopsy tests will be orderable and return discrete results in Epic.

When was the BillionToOne and Epic agreement signed for BLLN integration?

The agreement was signed in December 2025.

How does the Epic integration affect delivery of BLLN test results to patients?

Results are delivered into the Epic EHR and accessible via the MyChart patient portal to support a more connected patient experience.

What clinical benefits does the Epic-Aura integration provide for BLLN's UNITY Complete?

It enables clinicians to order UNITY Complete directly in the workflow and receive discrete fetal risk results for up to 14 conditions in the EHR.